Inhibition of receptor activator of NF-kappaB ligand by denosumab attenuates vascular calcium deposition in mice. - Wikidata - wikimedia - TriplyDB

Inhibition of receptor activator of NF-kappaB ligand by denosumab attenuates vascular calcium deposition in mice.

Inhibition of receptor activator of NF-kappaB ligand by denosumab attenuates vascular calcium deposition in mice.

http://www.wikidata.org/entity/Q37278407

about

Mechanisms of arterial calcifications and consequences for cardiovascular function New antiresorptive therapies for postmenopausal osteoporosis Molecular Mechanisms of Vascular Calcification in Chronic Kidney Disease: The Link between Bone and the Vasculature Long-term treatment of osteoporosis: safety and efficacy appraisal of denosumab Inflammation and the osteogenic regulation of vascular calcification: a review and perspective.Instructions for producing a mouse model of glucocorticoid-induced osteoporosis.Correlates of osteoprotegerin and association with aortic pulse wave velocity in patients with chronic kidney disease Correlation between osteoporosis and cardiovascular disease.Denosumab: targeting the RANKL pathway to treat rheumatoid arthritis.TRAIL-deficiency accelerates vascular calcification in atherosclerosis via modulation of RANKL.Runx2-upregulated receptor activator of nuclear factor κB ligand in calcifying smooth muscle cells promotes migration and osteoclastic differentiation of macrophages.Insights into aortic sclerosis and its relationship with coronary artery disease Extraskeletal benefits and risks of calcium, vitamin D and anti-osteoporosis medications Supraphysiologic glucocorticoid administration increased biomechanical bone strength of rats' vertebral body.Mechanisms and clinical consequences of vascular calcification The mechanism of vascular calcification - a systematic review.Smooth muscle cell-specific runx2 deficiency inhibits vascular calcification.Calcific Aortic Valve Disease: Molecular Mechanisms and Therapeutic Approaches Successful Management of Calciphylaxis in a Kidney Transplant Patient: Case Report.Denosumab could be a Potential Inhibitor of Valvular Interstitial Cells Calcification in vitro.Regression of vascular calcification in chronic kidney disease - feasible or fantasy? a review of the clinical evidence.RANKL inhibition with denosumab does not influence 3-year progression of aortic calcification or incidence of adverse cardiovascular events in postmenopausal women with osteoporosis and high cardiovascular risk.The Strategy to Prevent and Regress the Vascular Calcification in Dialysis Patients.Calcium Signaling in Interstitial Cells: Focus on Telocytes.Skeletal and extraskeletal actions of denosumab.Vascular calcification: an update on mechanisms and challenges in treatment Denosumab in osteoporosis.Recent advances in the role of cortisol and metabolic syndrome in age-related degenerative diseases.Osteoporosis and cardiovascular disease: an update.Arteriosclerosis and vascular calcification: causes, clinical assessment and therapy.Targeting local vascular and systemic consequences of inflammation on vascular and cardiac valve calcification.Deletion of a Distal RANKL Gene Enhancer Delays Progression of Atherosclerotic Plaque Calcification in Hypercholesterolemic Mice.Comparative Safety and Effectiveness of Denosumab Versus Zoledronic Acid in Patients With Osteoporosis: A Cohort Study.Increased calcification in osteoprotegerin-deficient smooth muscle cells: Dependence on receptor activator of NF-κB ligand and interleukin 6.Lanthanum carbonate prevents accelerated medial calcification in uremic rats: role of osteoclast-like activity.The connections between vascular calcification and bone health.Osteoprotegerin is independently associated with metabolic syndrome and microvascular complications in type 2 diabetes mellitus.Bisphosphonates, atherosclerosis and vascular calcification: update and systematic review of clinical studies.Omentin-1 attenuates arterial calcification and bone loss in osteoprotegerin-deficient mice by inhibition of RANKL expression.Vascular progenitor cells with decalcifying potential: a step toward prevention or treatment of atherosclerotic vascular calcification?

P2860

Q26821993-1DE17798-3840-42D6-88F7-FAD31048AF82 Q27014775-BDF14F97-CD4A-42FC-8161-238EBCB3B0BB Q28087423-E72359AA-3625-4C7B-8BFE-A170DB763C2C Q28727655-B3842E31-81D4-43F5-B8FB-81045F1C6B7B Q33782750-36712B1A-6152-4B5D-958B-B16C2C8AA4CD Q33990553-2105C61D-DCA0-4887-BA3A-53C561215709 Q34028264-D618B603-C770-408E-899F-D14D344B3357 Q34230303-1D1081CD-C243-469A-B0D5-8DFC03D3A449 Q34545263-957D6DDD-A6E6-4641-81C4-CB1B5A869FB6 Q34989869-C994B8B4-71AE-4DF8-B810-8C459C8B4F6C Q34993353-8912D8AE-9CFA-4446-A7E8-406BFAE202FA Q35070613-502BD8DD-F5A2-4158-8E22-515EB53E5A30 Q35740351-B0CAA46D-1296-48ED-8B18-1B5D9C3CAF72 Q35891408-20261952-E8E7-4CAB-94C5-9ED3D6317E01 Q36142207-539E75EB-6088-4302-8B4D-7E05E7FA1008 Q36577167-34C01D59-91D6-4985-ABE2-28BF1DE2080F Q36917940-0D01E245-6DC0-4FF0-8781-1AF476ADE5CB Q36956234-F6C093B1-2FE6-4B6C-84A8-1AC655DE93E9 Q37097806-240F98F5-C341-4AFF-B026-536B83031F6F Q37123162-BA27649C-13B7-4E2C-938E-7A12F68B49E7 Q37219046-3D96F0D4-616E-4095-B35B-216DA5861D51 Q37625447-47B854FB-7F94-466D-864B-D901284DF5E7 Q37670856-8C5B8B73-9E16-40F9-84AF-469CE2F4A944 Q37690948-5FB2105B-0692-4AA6-A2A8-92D3611AAB33 Q38009712-BE7ACE0D-6FF2-4175-9523-359DB6703E61 Q38086058-58413EA2-2DC5-4AB5-9DD8-8FC9C44FAD1B Q38167352-5BD0D299-2B4B-4D60-8635-1DA22163EDEF Q38392643-98B6EF87-3A33-488B-89C6-3166C9310CBF Q38513410-5CBAC3F7-5F05-4AC3-90A4-547D22A09C84 Q38543758-EEF09838-D7B5-483C-AE92-9DC14F2EE27B Q38703771-87B70E29-976C-4B78-8314-7B9C37538965 Q38832148-559AF73C-5714-4AEE-8A2F-64C3D2E60FBE Q39296189-A357D8DB-76EF-4D94-95A5-0B3AA8A07515 Q40719297-C0C23B47-F553-4223-8533-970FAC649D22 Q41846974-CCADBDF4-43F7-4469-AF7B-FB6955A2328D Q42917000-3831FBEC-B870-48C9-89AA-ECC4D62EFDE6 Q43743719-15093AC5-ECF2-422C-A081-59CDB24DCE94 Q44657342-B3A8AB08-8099-4E13-975D-F45E6D3F92D4 Q44791521-BC9E6DCA-83F0-4724-B6E4-F3CE5966D850 Q45898732-2D5E5463-16D7-45B2-92C6-D2363FE17577

P2860

Inhibition of receptor activator of NF-kappaB ligand by denosumab attenuates vascular calcium deposition in mice.

http://www.wikidata.org/entity/Q37278407

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 09 July 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Inhibition of receptor activat ...... ar calcium deposition in mice.

@en

Inhibition of receptor activat ...... ar calcium deposition in mice.

@nl

type

label

Inhibition of receptor activat ...... ar calcium deposition in mice.

@en

Inhibition of receptor activat ...... ar calcium deposition in mice.

@nl

prefLabel

Inhibition of receptor activat ...... ar calcium deposition in mice.

@en

Inhibition of receptor activat ...... ar calcium deposition in mice.

@nl

P1433

Q37278407-5A751384-9F9E-42CC-A39D-9B0FB7E5E7B3

P1476

Q37278407-A2EDC922-6E33-4BEA-BA83-4EFA33B9DE24

P2093

Q37278407-1166B83C-F601-4A06-8AC5-20D3AB588609

Q37278407-2905F43F-A15D-4D8B-9BB3-60C28410AD3E

Q37278407-33EA9963-877A-47CA-B3BD-9599ECC8E537

Q37278407-8515EF69-7D54-4B01-9BD4-5BCB6EBB487E

Q37278407-9EBF5C8D-D3FE-4093-B022-88F1C62D88DF

Q37278407-A05435D5-A992-4035-9178-01A9A47F31CB

Q37278407-AFF16BCC-62E3-4B6C-8A7C-5EFEE677CD45

Q37278407-C7AB4240-B2AA-4155-BF8F-D9C6249C9EF0

Q37278407-D410238E-43B3-47F0-8A4D-F8ACBD8345AF

P2860

Q37278407-02E4A20A-A5B9-4975-BB2A-D7F9228B935A

Q37278407-30FA810A-0153-438E-968F-91EEACAE1A83

Q37278407-3171F38D-8DA6-49AC-9C98-BF22129C6A9B

Q37278407-4B449244-A65A-4920-9AE9-805D4BF51013

Q37278407-4F67DE04-CBB5-46FF-BE81-F3EA9AE7691D

Q37278407-60571140-A370-4E69-997C-0150BC5B9354

Q37278407-6916E7A6-9DFE-4E1C-BC30-1A70233AA93F

Q37278407-866F4F8C-8442-4DF6-B1AC-54C13206BAD3

Q37278407-890EDDFA-7FFE-4CD2-A092-12FDDB9A1664

Q37278407-954D7923-E4D4-4E03-BB9A-8305EFFD9DA7

P304

Q37278407-8CFF1C74-F0EB-459C-BE7C-90070A9DAE81

P31

Q37278407-D66565AD-8B5B-4EE3-9D09-0623816F2A64

P356

Q37278407-4A1DFF27-7086-49D1-B541-1A667AE145E9

P407

Q37278407-AA7CA636-F5C7-473D-A5AF-0D1548BBBAE2

P433

Q37278407-3AB3689D-2C69-4E97-9D02-24114FF38460

P478

Q37278407-4F1A5E5C-FA91-4123-B120-15703225A47B

P50

Q37278407-5ebaa173-4cc3-335b-c099-febff513c364

Q37278407-c2882788-4bdd-697c-00b3-69844e5ecb45

P577

Q37278407-09C993A9-5B06-47C1-9049-F3867C698A36

P5875

Q37278407-D200D2B3-6464-4DF5-AE0D-DD6AA118D745

P698

Q37278407-F4EA8E74-6FCF-4130-BE45-5760479664A5

P921

Q37278407-33C4C6E3-CF81-4CA0-8B0B-3EAB6DB6E99A

P932

Q37278407-45705674-BC0C-4DC1-95B0-015317A7B077

P356

AJPATH.2009.080957

P1433

The American Journal of Pathology

P1476

Inhibition of receptor activat ...... ar calcium deposition in mice.

@en

P2093

Claudia Goettsch

http://www.w3.org/2001/XMLSchema#string

Henning Morawietz

http://www.w3.org/2001/XMLSchema#string

Lorenz C Hofbauer

http://www.w3.org/2001/XMLSchema#string

Michael Schoppet

http://www.w3.org/2001/XMLSchema#string

Paul J Kostenuik

http://www.w3.org/2001/XMLSchema#string

Reinhold G Erben

http://www.w3.org/2001/XMLSchema#string

Susann Helas

http://www.w3.org/2001/XMLSchema#string

Ute Hempel

http://www.w3.org/2001/XMLSchema#string

Ute Zeitz

http://www.w3.org/2001/XMLSchema#string

P2860

Mutation of the mouse klotho gene leads to a syndrome resembling ageing

The serum protein alpha 2-Heremans-Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification

Denosumab in postmenopausal women with low bone mineral density

The capability of plasma osteoprotegerin as a predictor of cardiovascular disease: a systematic literature review.

Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL.

Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases.

Molecular, endocrine, and genetic mechanisms of arterial calcification.

Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis.

Vascular calcification and osteoporosis--from clinical observation towards molecular understanding.

Glucocorticoid-induced osteoporosis: pathophysiology and therapy.

P304

473-478

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2353/AJPATH.2009.080957

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

175

http://www.w3.org/2001/XMLSchema#string

P50

Lorenz C Hofbauer

Henning Morawietz

P577

2009-07-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26659130

http://www.w3.org/2001/XMLSchema#string

P698

19590040

http://www.w3.org/2001/XMLSchema#string

P921

P932

2716948

http://www.w3.org/2001/XMLSchema#string